PARP inhibition demonstrated potent therapeutic efficacies in patients who were diagnosed with either metastatic breast or advanced ovarian cancers with germline BRCA1/2 mutations [43, 44]. This evidence concerns the gene BRCA1 and ovarian carcinoma.